Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Immuno-positron emission tomography (immunoPET) with 89Zr-labeled antibodies has
shown great potential in cancer imaging. It can provide important information about the …

PD-L1 immunohistochemistry correlates only moderately with patient survival and response
to PD-(L) 1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive …

Nanoscale metal–organic frameworks (nMOF) materials represent an attractive tool for
various biomedical applications. Due to the chemical versatility, enormous porosity, and …

The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

Chimeric antigen receptor (CAR) T cell therapy is a promising clinical approach for reducing
tumor progression and prolonging patient survival. However, improvements in both the …

Owing to improvements in our understanding of the biological principles of tumour initiation
and progression, a wide variety of novel targeted therapies have been developed …

Purpose Almost all radiolabellings of antibodies with 89 Zr currently employ the hexadentate
chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of 89 Zr in …

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …